Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trinity Biotech (TRIBY) -- Ignore unavailable to you. Want to Upgrade?

To: Keiko who wrote (7507)	12/15/1997 5:34:00 PM
From: Decci	Read Replies (1) \| Respond to of 14328

What was the management at BNT thinking? About money, perhaps. .-. OUT Monday December 15, 2:10 pm Eastern Time Company Press Release Bentley Pharm. Receives $9.8 Million From Warrant Conversion TAMPA, Fla.--(BW HealthWire)--Dec. 15, 1997--Bentley Pharmaceuticals Inc. (AMEX:BNT - news) Monday announced that in addition to the $8.6 million that the company had received from the exercise of its Class A warrants through Nov. 17, 1997, the company has received $1.2 million during the two week extension, resulting in a total of approximately $9.8 million. The company further stated that approximately 70 percent of all Class A warrants have been voluntarily exercised and that the terms of the remainder of the Class A warrants have reverted back to the original exercise price of $3.00 per share until their expiration on Feb. 14, 1999. Bentley's outstanding shares after the conversion total approximately 8.4 million. The Class B redeemable warrant discount period will remain open until Jan. 13, 1998, as previously announced. James R. Murphy, chairman and chief executive officer, stated in response to the infusion of capital: ''We are delighted by the vote of confidence from our shareholders and both acknowledge and appreciate their support. This completes the first step of the company's long range plan to generate the additional required working capital to assist in achieving Bentley's strategic objectives. We anticipate that the completion of these efforts will inaugurate a new and profitable era for Bentley Pharmaceuticals.'' Tampa-based Bentley Pharmaceuticals is an emerging international pharmaceutical company that leverages the competitive advantage of its manufacturing facility in Spain with its drug delivery technology to provide treatment for cardiovascular, gastrointestinal, neurological and infectious diseases. Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements which are not historical facts contained in this news release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, developments of new products, regulatory approval processes, the impact of competitive products or pricing, unpredictability of patent protection, technological changes, the effect of economic conditions and other uncertainties detailed in the company's filings with the Securities and Exchange Commission.